In this article, Dr. Tim Bull breaks down the recently released journal paper from the Crohn’s MAP Vaccine organization, entitled Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. This paper describes the initial safety studies in humans of a vaccine that is designed to stimulate immune recognition of specific components of the MAP bacterium. Dr. Tim Bull is a Reader in Infectious Diseases at St George’s, University of London. He is an internationally recognized expert in mycobacterial diseases and has over 20 years experience in working with culturing mycobacteria. He was instrumental in the initial design and development of the original vaccine and testing the efficacy of a prime-boost version in animals with MAP infection.

Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Read all the latest news and research about mycobacteria, particularly Mycobacterium avium subsp. paratuberculosis (MAP), and the treatment of Crohn’s and immune disease with AMAT and other innovative therapies. Enjoy!

In his latest article, John Aitken of Otakaro Pathways describes how they have identified bacteriological aspects of Crohn’s patients and some sarcoidosis patients that are not seen in healthy controls. A case study of a patient who recovered from cardiac sarcoidosis using antibiotic treatment is discussed, as is a 2019 trial. Take-aways detailing the activity of cell wall deficient mycobacteria in sarcoidosis included!

Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Read all the latest news and research about mycobacteria, particularly Mycobacterium avium subsp. paratuberculosis (MAP), and the treatment of Crohn’s and immune disease with AMAT and other innovative therapies. Enjoy!

In March 2018, the American College of Gastroenterology (ACG) released the 2018 Guidelines for the treatment of Crohn’s Disease (CD). Their conclusion, based on misinterpreted studies, that antimycobacterial therapy was not effective in inducing remission or mucosal healing in Crohn’s disease patients (page 498) prompted a response by some of the doctors in the Human Para community who have used AMAT with success. Read the letter that was published this week in the latest issue of Nature’s American Journal of Gastroenterology.